Revuforj

revumenib

Approval

ApplicationNDA 218944
Approval dateNov 15, 2024
Approval year2024
SponsorSyndax

FDA-approved use

To treat relapsed or refractory acute leukemia

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Revuforj: